AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30086434 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical marijuana use
Number of subjects: 307
Study 30086434 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical marijuana use over time
Number of subjects: 307
Study 30086434 — intervention group
Group type: COMPARATOR
Intervention: No marijuana use
Number of subjects: 307
Study 27776764 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Number of subjects: 0
Study 27776764 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic Field Stimulation
Number of subjects: 0
Study 27776764 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Number of subjects: 0
Study 24849104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2198
Study 24849104 — intervention group
Group type: COMPARATOR
Intervention: Heparins with routine GPI
Number of subjects: 2198
Study 24849104 — intervention group
Group type: COMPARATOR
Intervention: Heparins only with bailout GPI
Number of subjects: 2198
Study 22236796 — intervention group
Group type: EXPERIMENTAL
Intervention: onaBoNTA (200 IU injected into the bladder wall)
Number of subjects: 240
Study 20690893 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/day
Number of subjects: 0
Study 20690893 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin immediate-release 15 mg/day
Number of subjects: 0
Study 18759956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-based energy-restricted diet
Number of subjects: 32
Study 18759956 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 32
Study 15948985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 10 mg b.d.
Number of subjects: 143
Study 15948985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 20 mg b.d.
Number of subjects: 143
Study 15948985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 30 mg b.d.
Number of subjects: 143
Study 15948985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 12563622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (94 mg Ox + 26 mg Ca)
Number of subjects: 70
Study 12563622 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate (94 mg Ox + 430 mg Ca)
Number of subjects: 70
Study 10546919 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (8-ounce glass)
Number of subjects: 16
Study 10546919 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study 8904579 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 breathing for 10 min
Number of subjects: 16
Study 8904579 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing for 10 min
Number of subjects: 16
Study 8904579 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 breathing
Number of subjects: 16
Study 1846787 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at 6, 35, 200 or 1200 m-units min-1 m-2 for 2 hours
Number of subjects: 24
Study 1846787 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at higher rates
Number of subjects: 24
Study 1846787 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study 6439144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (rudimentary infarction)
Number of subjects: 80
Study 6439144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (subendocardial infarct)
Number of subjects: 80
Study 6439144 — intervention group
Group type: COMPARATOR
Intervention: Group C (inferior wall infarcts)
Number of subjects: 80
Study 6439144 — intervention group
Group type: COMPARATOR
Intervention: Group D (transmural anterior infarcts)
Number of subjects: 80
Study 6439144 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (treated medically)
Number of subjects: 80
Study 31651531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 1950
Study 31651531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1950
Study 29500678 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message support (daily text message for 1 year)
Number of subjects: 95
Study 29500678 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 95
Study 26488759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic induction
Number of subjects: 121
Study 26488759 — intervention group
Group type: COMPARATOR
Intervention: Listening to music (control condition)
Number of subjects: 121
Study 24790271 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 66
Study 24790271 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 66
Study 22326210 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered hypertonic saline (BHS)
Number of subjects: 81
Study 22326210 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NSS)
Number of subjects: 81
Study 20303287 — intervention group
Group type: COMPARATOR
Intervention: Single-row repair
Number of subjects: 68
Study 20303287 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row repair
Number of subjects: 68
Study 18557842 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 2127
Study 18557842 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) plus revised ISFP (SFP 10-14)
Number of subjects: 2127
Study 18557842 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2127
Study 15942495 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 480
Study 15942495 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 480
Study 11794433 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 220
Study 11794433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 10422654 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 10422654 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 60
Study 8583793 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 2.5 mg
Number of subjects: 0
Study 8583793 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 5 mg
Number of subjects: 0
Study 2125013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponalrestat
Number of subjects: 30
Study 2125013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6277642 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 (5 mg i.m.)
Number of subjects: 16
Study 6277642 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 2766 (20 mg i.m.)
Number of subjects: 16
Study 6277642 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (10 micrograms/kg i.v.)
Number of subjects: 16
Study 6277642 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptides with non-alcoholic drink
Number of subjects: 16
Study 6277642 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (1.5 g/kg)
Number of subjects: 16
Study 30251205 — intervention group
Group type: EXPERIMENTAL
Intervention: ASXL2 mutations
Number of subjects: 41
Study 30251205 — intervention group
Group type: EXPERIMENTAL
Intervention: ZBTB7A mutations
Number of subjects: 41
Study 30251205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohesin complex gene mutations
Number of subjects: 41
Study 28486721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided LASIK
Number of subjects: 22
Study 28486721 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 22
Study 26113580 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, cyclophosphamide, and paclitaxel, dosed by actual body weight
Number of subjects: 1909
Study 23538148 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training (OLT)
Number of subjects: 181
Study 23538148 — intervention group
Group type: EXPERIMENTAL
Intervention: OLT plus motivational enhancement (ME)
Number of subjects: 181
Study 23538148 — intervention group
Group type: EXPERIMENTAL
Intervention: OLT+ME plus a learning community
Number of subjects: 181
Study 21345942 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion
Number of subjects: 12
Study 21345942 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg/day)
Number of subjects: 12
Study 21345942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21345942 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (vasodilator control)
Number of subjects: 12
Study 19969220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric silicone monofocal IOL (MS 612 ASP‐Y) implanted in the capsular bag followed by sulcus placement of an add‐on multifocal IOL (MS 714 PB) with a +3.50 D diffractive element.
Number of subjects: 30
Study 16982107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 502
Study 16982107 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (Met)
Number of subjects: 502
Study 16982107 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM plus Met
Number of subjects: 502
Study 16982107 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 502
Study 15372382 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency (80 degrees C, 60 seconds)
Number of subjects: 33
Study 15372382 — intervention group
Group type: COMPARATOR
Intervention: Voltage-controlled radiofrequency (20 V, 60 seconds)
Number of subjects: 33
Study 11740193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg once daily for the first 2 weeks)
Number of subjects: 229
Study 11740193 — intervention group
Group type: COMPARATOR
Intervention: No Prednisolone
Number of subjects: 229
Study 11740193 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP group
Number of subjects: 229
Study 11740193 — intervention group
Group type: COMPARATOR
Intervention: Non-NVP group
Number of subjects: 229
Study 11740193 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline CD4 cell count
Number of subjects: 229
Study 9922474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate infusions (30 or 45 mg weekly)
Number of subjects: 20
Study 9922474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate infusions (30 or 45 mg every three months or 90 mg every six months)
Number of subjects: 20
Study 8118635 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator (BD) treatment
Number of subjects: 169
Study 2784606 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction
Number of subjects: 152
Study 2784606 — intervention group
Group type: COMPARATOR
Intervention: Thiopental induction
Number of subjects: 152
Study 4890207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 20
Study 4890207 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine-prednisolone combination
Number of subjects: 20
Study 4890207 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine-prednisolone treatment prolonged to one year
Number of subjects: 20
Study 4890207 — intervention group
Group type: COMPARATOR
Intervention: Control (Prednisolone)
Number of subjects: 20
Study 30380584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 103
Study 30380584 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy (PDT)
Number of subjects: 103
Study 30380584 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 103
Study 28445097 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.1 mg
Number of subjects: 227
Study 28445097 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 227
Study 28445097 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.4 mg
Number of subjects: 227
Study 28445097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 25175629 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver alginate dressing
Number of subjects: 500
Study 25175629 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing
Number of subjects: 500
Study 22770506 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 44
Study 22770506 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 44
Study 22770506 — intervention group
Group type: COMPARATOR
Intervention: Swimming
Number of subjects: 44
Study 22770506 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 21467231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 minutes, 5 times a week for 16 weeks)
Number of subjects: 391
Study 21467231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 391
Study 19173833 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-field lymph node dissection (Three-FD)
Number of subjects: 122
Study 19173833 — intervention group
Group type: COMPARATOR
Intervention: Two-field lymph node dissection (Two-FD)
Number of subjects: 122
Study 17702264 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 830
Study 14977031 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical body position (head rotated 68 degrees clockwise or counterclockwise)
Number of subjects: 0
Study 14977031 — intervention group
Group type: COMPARATOR
Intervention: Symmetrical body position (sitting in a completely symmetrical position)
Number of subjects: 0
Study 11841126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucare presented in an individual format
Number of subjects: 225
Study 11841126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucare presented in a group format
Number of subjects: 225
Study 11841126 — intervention group
Group type: COMPARATOR
Intervention: non‐directive supportive group
Number of subjects: 225
Study 11841126 — intervention group
Group type: COMPARATOR
Intervention: no‐intervention control
Number of subjects: 225
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteolin (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Myricetin (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferol (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercitrin (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Apigenin (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin-3-glucoside (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutin (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (279 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (23.2 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (23.2 micromol/L)
Number of subjects: 0
Study 9625095 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin and Vitamin C (23.2 micromol/L each)
Number of subjects: 0
Study 7883394 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 14
Study 3375957 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurectomy for diffuse malignant mesothelioma
Number of subjects: 0
Study 3375957 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapleural pneumonectomy for diffuse malignant mesothelioma
Number of subjects: 0
Study 3375957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for lung cancer in asbestos-exposed patients
Number of subjects: 0
Study 3375957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for benign pleural plaques
Number of subjects: 0
Study 30388439 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine-rich plant extract supplement
Number of subjects: 30
Study 30388439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27342073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT): 4×4-min intervals at 85-95% maximum heart rate (HRmax) with a 4-min recovery period at 65% HRmax.
Number of subjects: 60
Study 27342073 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT): Completing a resistance circuit until an expenditure of 500 kcal at 40-80% of one-rep max (1RM) has been achieved.
Number of subjects: 60
Study 27342073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (HIIT + RT): Combination of both HIIT and RT interventions.
Number of subjects: 60
Study 27342073 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group: usual care with dietary support.
Number of subjects: 60
Study 24941837 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Chinese medical treatment (CM treatment) as maintenance therapy
Number of subjects: 69
Study 24941837 — intervention group
Group type: COMPARATOR
Intervention: Western drug chemotherapy (Gemcitabine or Alimta or docetaxel)
Number of subjects: 69
Study 22619193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of 4 mg/mL dexamethasone sodium phosphate
Number of subjects: 82
Study 22619193 — intervention group
Group type: COMPARATOR
Intervention: 1 mL of normal saline (placebo)
Number of subjects: 82
Study 20927003 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Number of subjects: 76
Study 18256391 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 1071
Study 18256391 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 1071
Study 16085220 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of a soluble TNF receptor (TNFR:Fc, etanercept, Enbrel) 25mg subcutaneously, twice weekly for 2 weeks
Number of subjects: 26
Study 16085220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11918622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (hydroxymethylglutaryl coenzyme A reductase inhibitor)
Number of subjects: 2838
Study 11918622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study 10400847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS) 25 microgram once daily
Number of subjects: 679
Study 10400847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS) 100 microgram once daily
Number of subjects: 679
Study 10400847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (MFNS) 200 microgram once daily
Number of subjects: 679
Study 10400847 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 84 microgram twice daily (168 microgram/day)
Number of subjects: 679
Study 10400847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 679
Study 7734238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 32
Study 7734238 — intervention group
Group type: COMPARATOR
Intervention: Austin-Moore hemiarthroplasty
Number of subjects: 32
Study 2139269 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the peritoneal layer with continuous catgut
Number of subjects: 0
Study 2139269 — intervention group
Group type: COMPARATOR
Intervention: Omission of closure of the peritoneal layer
Number of subjects: 0
Study 524479 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium splint for one week
Number of subjects: 200
Study 524479 — intervention group
Group type: COMPARATOR
Intervention: Plaster of Paris immobilization for three weeks
Number of subjects: 200
Study 29939060 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session brief intervention targeting alcohol misuse with personalized feedback and psychoeducation on PTSD symptoms and coping
Number of subjects: 68
Study 29939060 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview accompanying feedback
Number of subjects: 68
Study 29939060 — intervention group
Group type: COMPARATOR
Intervention: Feedback only (without motivational interview)
Number of subjects: 68
Study 28558855 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality fish oil
Number of subjects: 54
Study 28558855 — intervention group
Group type: COMPARATOR
Intervention: Oxidised fish oil
Number of subjects: 54
Study 28558855 — intervention group
Group type: COMPARATOR
Intervention: High-oleic sunflower oil (HOSO)
Number of subjects: 54
Study 26402001 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil plus choline alphoscerate
Number of subjects: 113
Study 26402001 — intervention group
Group type: COMPARATOR
Intervention: Donepezil alone
Number of subjects: 113
Study 23668667 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐Smoke intervention
Number of subjects: 341
Study 23668667 — intervention group
Group type: COMPARATOR
Intervention: Web‐Nutrition control
Number of subjects: 341
Study 23668667 — intervention group
Group type: COMPARATOR
Intervention: Didactic control
Number of subjects: 341
Study 23668667 — intervention group
Group type: COMPARATOR
Intervention: Group control
Number of subjects: 341
Study 21343698 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY‐TT (GlaxoSmithKline Biologicals)
Number of subjects: 1025
Study 21343698 — intervention group
Group type: COMPARATOR
Intervention: Men‐PS (Mencevax™)
Number of subjects: 1025
Study 21343698 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY‐TT
Number of subjects: 1025
Study 21343698 — intervention group
Group type: COMPARATOR
Intervention: ACWY‐TT and Men‐PS
Number of subjects: 1025
Study 19039596 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 30
Study 19039596 — intervention group
Group type: COMPARATOR
Intervention: Partial division of puborectalis (PDPR)
Number of subjects: 30
Study 17503885 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 20 mg every 8 hours, starting 15 days before PCI and continuing for 3 months after the procedure.
Number of subjects: 52